Inovio Pharmaceuticals (INO) Total Current Liabilities (2010 - 2026)

Inovio Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $37.9 million in Q1 2026.

• Quarterly Total Current Liabilities rose 38.78% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.9 million (up 38.78% YoY) and the FY2025 annual result came in at $43.7 million, up 23.62% from the prior year.
• Total Current Liabilities eased to $37.9 million in Q1 2026 per INO's latest filing, from $43.7 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $131.1 million in Q2 2022 and troughed at $23.4 million in Q1 2024.
• A 5-year average of $52.6 million and a median of $43.7 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 60.38% in 2023, then surged 197.13% in 2025.
• Over 5 years, Total Current Liabilities stood at $96.9 million in 2022, then tumbled by 56.05% to $42.6 million in 2023, then slipped by 17.02% to $35.3 million in 2024, then grew by 23.62% to $43.7 million in 2025, then decreased by 13.16% to $37.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $37.9 million, $43.7 million, and $69.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.